Margarita is Managing Director at Abbvie Ventures. Margarita has lead investments in over a dozen biotech companies in the U.S. and Europe. She is responsible AbbVie Ventures’ investments in Alector, Morphic Therapeutics, CARISMA Therapeutics, and Jnana Therapeutics, among others.
Margarita brings over 20 years of dealmaking experience, with over a decade of biotech licensing, IPOs and acquisitions. As a Director with Abbott’s Global Pharmaceutical Licensing & Acquisitions, she was involved in the in-licensing of Elagolix, the acquisition of Solvay and Immuven, and the acquisition of the Lupron franchise. Before joining Abbott, Margarita practiced as a corporate and securities lawyer in Silicon Valley with the firm of Brobeck Phleger & Harrison.
Beyond AbbVie Ventures, Margarita currently serves on the Boards of the New England Venture Capital Association, the MidAmerica Healthcare Investors Network and P33 Chicago. Margarita received her bachelor’s degree from Santa Clara University and her juris doctor from Santa Clara University School of Law.